Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)
12 Junio 2023 - 3:00PM
Business Wire
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage
biopharmaceutical company focused on developing and commercializing
novel therapies for rare endocrine disorders with significant unmet
medical need, today announced that a submitted abstract was
accepted for the 105th Annual Meeting of the Endocrine Society
(ENDO 2023) taking place June 15-18, 2023, in Chicago. In a poster
presentation, the company will highlight the effect of tildacerfont
on gonadotropins and testicular steroidogenesis in men with classic
congenital adrenal hyperplasia (CAH).
ENDO 2023 presentation details are as follows:
Title: Effect of tildacerfont on gonadotropins and
testicular steroidogenesis in men with classic 21-hydroxylase
deficiency Session Title: P72 – Clinical Adrenal and
Pituitary: Adrenal Insufficiency Session Date & Time:
1:00 p.m. – 2:00 p.m. CT on June 17, 2023 Presenter: Will
Charlton, M.D., M.A.S., Chief Medical Officer, Spruce Biosciences
Authors: Ahmed Khattab, M.D., Will Charlton, M.D., M.A.S.,
and Richard Auchus, M.D., Ph.D.
The poster will be available on the company’s website beginning
June 17, 2023, at 2:00 p.m. CT. Access more information about ENDO
2023 here.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company
focused on developing and commercializing novel therapies for rare
endocrine disorders with significant unmet medical need. Spruce is
initially developing its wholly-owned product candidate,
tildacerfont, as the potential first non-steroidal therapy for
patients suffering from classic congenital adrenal hyperplasia
(CAH). Spruce is also developing tildacerfont for women suffering
from polycystic ovary syndrome (PCOS) with primary adrenal androgen
excess. To learn more, visit www.sprucebiosciences.com and follow
us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230612005110/en/
Media Will Zasadny Evoke Canale (619) 961-8848
will.zasadny@evokecanale.com media@sprucebio.com
Investors Xuan Yang Solebury Strategic Communications
(415) 971-9412 xyang@soleburystrat.com investors@sprucebio.com
Spruce Biosciences (NASDAQ:SPRB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Spruce Biosciences (NASDAQ:SPRB)
Gráfica de Acción Histórica
De May 2023 a May 2024
